DK1503759T3 - Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser heraf - Google Patents
Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser herafInfo
- Publication number
- DK1503759T3 DK1503759T3 DK03726824T DK03726824T DK1503759T3 DK 1503759 T3 DK1503759 T3 DK 1503759T3 DK 03726824 T DK03726824 T DK 03726824T DK 03726824 T DK03726824 T DK 03726824T DK 1503759 T3 DK1503759 T3 DK 1503759T3
- Authority
- DK
- Denmark
- Prior art keywords
- derivatives
- carboxylic acids
- sub
- site
- action
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38064102P | 2002-05-14 | 2002-05-14 | |
| PCT/US2003/014948 WO2003097564A2 (en) | 2002-05-14 | 2003-05-12 | Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1503759T3 true DK1503759T3 (da) | 2009-04-14 |
Family
ID=29549994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03726824T DK1503759T3 (da) | 2002-05-14 | 2003-05-12 | Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser heraf |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7355047B2 (da) |
| EP (1) | EP1503759B1 (da) |
| JP (1) | JP4532263B2 (da) |
| KR (1) | KR20040107525A (da) |
| CN (1) | CN1652784A (da) |
| AT (1) | ATE417613T1 (da) |
| AU (1) | AU2003229043B2 (da) |
| BR (1) | BR0309965A (da) |
| CA (1) | CA2484308A1 (da) |
| DE (1) | DE60325347D1 (da) |
| DK (1) | DK1503759T3 (da) |
| ES (1) | ES2319176T3 (da) |
| HK (1) | HK1072905A1 (da) |
| IL (1) | IL164734A0 (da) |
| MX (1) | MXPA04011156A (da) |
| NZ (1) | NZ536061A (da) |
| WO (1) | WO2003097564A2 (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| DE60325347D1 (de) * | 2002-05-14 | 2009-01-29 | Univ California | Substituierte chinoloncarbonsäuren, ihre derivate, wirkungsort und anwendungen |
| DE102004004971B3 (de) * | 2004-01-31 | 2005-09-15 | Aventis Pharma Deutschland Gmbh | Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel |
| US7470706B2 (en) | 2004-01-31 | 2008-12-30 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| AU2005240657A1 (en) * | 2004-05-06 | 2005-11-17 | The Regents Of The University Of California | Substituted enaminones, their derivatives and uses thereof |
| US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| LT2489659T (lt) | 2004-06-24 | 2018-03-26 | Vertex Pharmaceuticals Incorporated | Atp rišančios kasetės transporterių moduliatoriai |
| CA2605384A1 (en) * | 2005-04-11 | 2006-10-19 | F. Hoffman-La Roche Ag | (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines |
| CN101171238B (zh) * | 2005-05-04 | 2010-12-15 | 弗·哈夫曼-拉罗切有限公司 | 对5-ht受体具有活性的(3,4-二氢-喹唑啉-2-基)-(2-芳氧基-乙基)胺 |
| CA2631917A1 (en) * | 2005-12-05 | 2007-06-14 | Merck & Co., Inc. | Quinolone m1 receptor positive allosteric modulators |
| US20090105272A1 (en) * | 2005-12-24 | 2009-04-23 | Grootenhuis Peter D J | Prodrugs of modulators of ABC transporters |
| RS60205B1 (sr) | 2005-12-28 | 2020-06-30 | Vertex Pharma | Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida |
| PL2383271T3 (pl) * | 2006-03-13 | 2013-12-31 | Kyorin Seiyaku Kk | Aminochinolony jako inhibitory GSK-3 |
| EP2064185B1 (en) * | 2006-08-10 | 2011-06-08 | Ferrer Internacional, S.A. | 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions |
| EP1886996A1 (en) * | 2006-08-10 | 2008-02-13 | Ferrer Internacional, S.A. | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions |
| EP2074123B1 (en) * | 2006-10-16 | 2012-12-05 | Bionomics Limited | Novel anxiolytic compounds |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| WO2009040377A2 (en) * | 2007-09-27 | 2009-04-02 | Ge Healthcare Limited | Imaging agents |
| WO2010047990A1 (en) * | 2008-10-23 | 2010-04-29 | Merck Sharp & Dohme Corp. | Fused heterocyclic m1 receptor positive allosteric modulators |
| KR101955863B1 (ko) | 2009-03-20 | 2019-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
| US20120093917A1 (en) * | 2009-04-02 | 2012-04-19 | Robert Hromas | Metnase and intnase inhibitors and their use in treating cancer |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| JP2014510065A (ja) | 2011-03-02 | 2014-04-24 | バイオノミックス リミテッド | 治療薬としての新規な小分子 |
| WO2012116410A1 (en) * | 2011-03-02 | 2012-09-07 | Bionomics Limited | Methods of treating a disease or condition of the central nervous system |
| US9133188B2 (en) | 2011-05-12 | 2015-09-15 | Bionomics Limited | Methods for preparing naphthyridines |
| NZ629199A (en) | 2012-02-27 | 2017-01-27 | Vertex Pharma | Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
| CN107501107A (zh) * | 2017-09-26 | 2017-12-22 | 兰亚朝 | 喹诺酮药物的中间体合成方法 |
| CN111269131B (zh) * | 2020-03-12 | 2021-12-28 | 江苏飞宇医药科技股份有限公司 | 以三正丙胺为吸酸剂制备环丙乙酯胺化物的工艺 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1433774A (en) * | 1973-02-26 | 1976-04-28 | Allen & Hanburys Ltd | Heterocyclic compounds apparatus for conveying articles |
| JPS5715760B2 (da) * | 1974-06-11 | 1982-04-01 | ||
| US4390541A (en) * | 1980-12-19 | 1983-06-28 | Lilly Industries Limited | Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease |
| US6248739B1 (en) * | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
| ES2235883T3 (es) * | 1999-05-06 | 2005-07-16 | Neurogen Corporation | 4-oxo-quinolino-3-carboxamidas sustituidas: ligandos de receptores cerebrales gaba. |
| GB0127349D0 (en) * | 2001-11-14 | 2002-01-02 | Glaxo Group Ltd | Macrolides |
| DE60325347D1 (de) * | 2002-05-14 | 2009-01-29 | Univ California | Substituierte chinoloncarbonsäuren, ihre derivate, wirkungsort und anwendungen |
-
2003
- 2003-05-12 DE DE60325347T patent/DE60325347D1/de not_active Expired - Lifetime
- 2003-05-12 AU AU2003229043A patent/AU2003229043B2/en not_active Ceased
- 2003-05-12 CA CA002484308A patent/CA2484308A1/en not_active Abandoned
- 2003-05-12 US US10/514,808 patent/US7355047B2/en not_active Expired - Fee Related
- 2003-05-12 AT AT03726824T patent/ATE417613T1/de not_active IP Right Cessation
- 2003-05-12 DK DK03726824T patent/DK1503759T3/da active
- 2003-05-12 NZ NZ536061A patent/NZ536061A/en unknown
- 2003-05-12 ES ES03726824T patent/ES2319176T3/es not_active Expired - Lifetime
- 2003-05-12 BR BR0309965-2A patent/BR0309965A/pt not_active IP Right Cessation
- 2003-05-12 KR KR10-2004-7018340A patent/KR20040107525A/ko not_active Application Discontinuation
- 2003-05-12 MX MXPA04011156A patent/MXPA04011156A/es active IP Right Grant
- 2003-05-12 EP EP03726824A patent/EP1503759B1/en not_active Expired - Lifetime
- 2003-05-12 WO PCT/US2003/014948 patent/WO2003097564A2/en active Application Filing
- 2003-05-12 JP JP2004505299A patent/JP4532263B2/ja not_active Expired - Fee Related
- 2003-05-12 CN CNA03810816XA patent/CN1652784A/zh active Pending
-
2004
- 2004-10-20 IL IL16473404A patent/IL164734A0/xx unknown
-
2005
- 2005-08-02 HK HK05106618.4A patent/HK1072905A1/xx not_active IP Right Cessation
-
2008
- 2008-02-15 US US12/032,403 patent/US20080176897A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2319176T3 (es) | 2009-05-05 |
| ATE417613T1 (de) | 2009-01-15 |
| KR20040107525A (ko) | 2004-12-20 |
| NZ536061A (en) | 2008-09-26 |
| HK1072905A1 (en) | 2005-09-16 |
| JP2005535592A (ja) | 2005-11-24 |
| WO2003097564A3 (en) | 2004-02-26 |
| US20080176897A1 (en) | 2008-07-24 |
| CN1652784A (zh) | 2005-08-10 |
| JP4532263B2 (ja) | 2010-08-25 |
| EP1503759B1 (en) | 2008-12-17 |
| IL164734A0 (en) | 2005-12-18 |
| AU2003229043A1 (en) | 2003-12-02 |
| WO2003097564A2 (en) | 2003-11-27 |
| EP1503759A2 (en) | 2005-02-09 |
| DE60325347D1 (de) | 2009-01-29 |
| US7355047B2 (en) | 2008-04-08 |
| AU2003229043B2 (en) | 2008-12-04 |
| CA2484308A1 (en) | 2003-11-27 |
| US20060178516A1 (en) | 2006-08-10 |
| EP1503759A4 (en) | 2006-02-15 |
| MXPA04011156A (es) | 2005-02-17 |
| BR0309965A (pt) | 2005-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1503759T3 (da) | Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser heraf | |
| WO2005118719A3 (en) | Production of 3-hydroxypropionic acid using beta-alanine/pyruvate aminotransferase | |
| UA85711C2 (ru) | Замещенные енаминоны, их производные и их применение | |
| DK1805129T3 (da) | (Biphenyl-)carboxylsyrer og derivater deraf | |
| NO20035603D0 (no) | Fluorpyrrolidiner som dipeptidyl peptidase inhibitorer | |
| TR200103493T2 (tr) | Metaloproteaz önleyicileri | |
| ATE380175T1 (de) | Pyrrolidine als dipeptidyl peptidase inhibitoren | |
| CY1107688T1 (el) | Δικυκλικες ενωσεις πυρρολιδινης | |
| NO20072767L (no) | Gabapentin prodrug vedvarende frigivelse orale doseringsformer | |
| DK1641764T3 (da) | P38-kinasehæmmere på grundlag af 5-leddede heterocykliske forbindelser | |
| NL1025946A1 (nl) | Alfa-gesubstitueerde carbonzuren als PPAR-modulatoren. | |
| DK1311256T3 (da) | Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser | |
| HUP0401647A2 (hu) | Új béta-fenil-alfa-oxi-propionsav-származékok, előállítási eljárásaik és gyógyszerészetileg fontos vegyületek előállításánál történő felhasználásuk | |
| NO20056161L (no) | Formuleringer for behandling av artrittilstander | |
| DK0678087T3 (da) | Forbindelser med selektiv aktivitet til retinoid-X-receptorer og metoder til modulering af processer medieret af retinoid-X | |
| DK0946176T3 (da) | Anvendelse af 7-(2-oxa-5,8-diazabicyclo[4.3.0]quinoloncarboxylsyre- og naphthydridoncarboxylsyrederivater til fremstilling af et lægemiddel til behandling af Helicobacter-pylori-infektioner og dermed associerede gastroduodenale sygdomme | |
| IS8231A (is) | Lyfjafræðilega gagnleg sölt karboxýlsýruafleiða | |
| NO20052753D0 (no) | Kombinasjonsprodukter med karboksylsyrederivater som inhiberer bindingen av integriner til deres reseptorer, og andre terapeutiske forbindelser. | |
| AU2003293311A8 (en) | Secondary binding site of dipeptidyl peptidase iv (dp iv) | |
| UY27618A1 (es) | Ésteres hidroxamato de ácido n-(4-fenil-sustituido)-antranílico | |
| NO20040389L (no) | Nye vinylkarboksylsyrederivater og deres anvendelse som antidiabetika | |
| FR2809595B1 (fr) | Derive laitier presentant une composition minerale et en acides amines selectivement modifiee, procedes pour sa fabrication, et utilisation. | |
| IS8232A (is) | Lyfjafræðilega gagnleg sölt karboxýlsýruafleiða | |
| NO20033949L (no) | Sammensetning og fremgangsmåte til å behandle neoplastiske sykdommer assosiert med forhöyede matriks metalloproteinaseaktiviteter ved åbenytte katechinforbindelser | |
| DK1363876T3 (da) | Glucocorticoidreceptormodulatorer |